ERBB2 and breast carcinoma: The utility of a single-antibody therapy applied to abnormal tumor-related surface expression is exemplified by trastuzumab for HER2+ breast cancer (27), especially when the trastuzumab is conjugated with highly cytotoxic drugs such as emtansine or deruxtecan (28, 29).